Effective June 6, 2016, Spectrum Health Regional Laboratory Molecular Diagnostics Department is pleased to announce the addition of the MPN Expanded Panel (Test #7090, Epic #LAB3611).
Myeloproliferative neoplasms (MPN) Expanded panel uses next generation sequencing (NGS) and fragmentation analysis to detected well-defined, recurrent mutations in JAK2 exon 12, MPL and CALR genes, which, in addition to BCR-ABL gene fusion and JAK2 V617F mutation (testing, provides a comprehensive approach to aiding in the diagnosis of MPN. The MPN Expanded Panel can be ordered concurrently with JAK2 V617F (Test #9066, Epic #LAB3066) testing or as a reflex order if JAK2 V617F testing is negative (Test #7093, Epic #LAB3612). The same sample can be used for both JAK2 V617F and MPN Expanded Panel testing. This assay has been validated in the CLIA-certified Advanced Technology Laboratory (ATL) for clinical use.
Questions may be direct to Dr. Cong Liu, PHD, FACMG, Molecular Diagnostic’s Technical Director.